- Advertise
- About OncLive
- Editorial Board
- MJH Life Sciences brands
- Contact Us
- Privacy
- Terms & Conditions
- Do Not Sell My Information
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
© 2025 MJH Life Sciences™ and OncLive - Clinical Oncology News, Cancer Expert Insights. All rights reserved.
Latest Conference Articles
The OncLive® Conference page includes a listing of all conferences covered by OncLive®, including the ASCO, ESMO, SITC, EHA, ASH, and SABCS annual meetings, as well as the Chemotherapy Foundation Symposium and Miami Breast Cancer Conference, among many others. Conference coverage incorporates articles and interviews in written and video format.
Cabozantinib Plus Atezolizumab Shows Promise in mCRPC
May 31st 2020, 10:39pm
The combination of cabozantinib and atezolizumab showed clinically meaningful activity in patients with metastatic castration-resistant prostate cancer.
Darolutamide Improves OS, Delays Onset of Cancer-Related Morbidity and Subsequent Chemo in Nonmetastatic CRPC
May 31st 2020, 10:05pm
Darolutamide (Nubeqa) plus androgen deprivation therapy led to a 31% reduction in the risk of death compared with placebo and ADT in patients with nonmetastatic castration-resistant prostate cancer.
IMvigor010 Misses DFS End Point in Muscle-Invasive Urothelial Carcinoma
May 31st 2020, 8:58pm
The phase 3 IMvigor010 trial comparing adjuvant atezolizumab with observation in patients with muscle-invasive urothelial carcinoma failed to meet its primary endpoint of disease-free survival.
Cabozantinib Maintains Efficacy in Advanced RCC Irrespective of Prior Treatment
May 31st 2020, 5:52pm
Patients with advanced renal cell carcinoma who were treated with cabozantinib (Cabometyx) following both immunotherapy and non-IO regimens demonstrated promising responses.
Pyrotinib Combo Improves PFS in HER2+ Metastatic Breast Cancer
May 31st 2020, 5:31pm
Pyrotinib plus capecitabine achieved a better progression-free survival than lapatinib plus capecitabine in patients with HER2-positive metastatic breast cancer previously treated with trastuzumab and chemotherapy.
Longer Follow-Up for Cemiplimab Confirms Superior Efficacy Over Other Regimens for CSCC
May 31st 2020, 5:22pm
In the phase 2 trial EMPOWER-CSCC-1, up to 3 years of follow-up showed continued response rates, and a clinically meaningful survival and duration of response for cemiplimab-rwlc in patients with advanced cutaneous squamous cell carcinoma.
Baseline and Posttreatment ctDNA Positivity Linked to Poor Prognosis, rPFS in mCRPC
May 31st 2020, 5:18pm
Baseline and posttreatment circulating tumor DNA positivity was associated with worse radiologic progression-free survival in patients with metastatic castration-resistant prostate cancer.
Frontline Pembrolizumab/Axitinib Survival Benefit Upholds in Advanced RCC
May 31st 2020, 3:32am
The combination of pembrolizumab and axitinib continued to demonstrate a clinically significant improvement in progression-free and overall survival compared with sunitinib in patients with previously untreated, advanced renal cell carcinoma.
Dr. Van Tine on Next Steps With ADP-A2M4 in Advanced Solid Tumors
May 31st 2020, 2:35am
Brian A. Van Tine, MD, PhD, discusses next steps with ADP-A2M4 SPEAR T cells in advanced solid tumors.
Tislelizumab Frontline Combos Extend PFS in Squamous NSCLC
May 31st 2020, 2:00am
Combining the anti–PD-1 agent tislelizumab with chemotherapy improved progression-free survival compared with chemotherapy alone as a frontline treatment in Chinese patients with advanced squamous non–small cell lung cancer.
Frontline Durvalumab Maintains OS Benefit in Extensive-Stage Small Cell Lung Cancer
May 31st 2020, 1:37am
The addition of durvalumab to standard chemotherapy continued to demonstrate an improvement in overall survival for patients with treatment-naïve extensive-stage small cell lung cancer.
Cabozantinib/Atezolizumab Combo Shows Promise in Previously Treated Urothelial Carcinoma
May 31st 2020, 1:08am
The combination of cabozantinib (Cabometyx) and atezolizumab (Tecentriq) demonstrated promising objective responses in patients with urothelial carcinoma who progressed after receiving platinum-containing chemotherapy.
Interim ZUMA-5 Analysis Shows Promise for Axi-Cel in Relapsed/Refractory iNHL
May 31st 2020, 1:05am
Axicabtagene ciloleucel (axi-cel; Yescarta) demonstrated significant and durable clinical benefit as well as a manageable safety profile in patients with relapsed or refractory indolent non-Hodgkin lymphoma.
Trastuzumab Deruxtecan Shows Promising Clinical Activity in CRC and Gastric/GEJ Tumors
May 31st 2020, 12:47am
Fam-trastuzumab deruxtecan-nxki (Enhertu) demonstrated promising clinical activity in patients with HER2-positive metastatic colorectal cancer, as well as in those with HER2-positive advanced gastric or gastroesophageal junction adenocarcinoma.
Teclistamab Appears Safe at All Doses for Relapsed/Refractory Myeloma Treatment
May 31st 2020, 12:29am
Teclistamab (JNJ-64007957) appeared to be a safe and efficacious treatment for patients with relapsed/refractory multiple myeloma.
Apalutamide Plus ADT Leads to Significantly Improved Outcomes in Nonmetastatic CRPC
May 31st 2020, 12:08am
Results from the phase III SPARTAN trial showed that apalutamide plus androgen deprivation therapy significantly improved overall survival when compared with ADT plus placebo in patients with nonmetastatic castration-resistant prostate cancer.
KTE-X19 Demonstrates Comparable Pharmacologic, Clinical Outcomes to Approved Therapies in MCL
May 30th 2020, 11:57pm
The pharmacodynamic profile of KTE-X19, an autologous anti-CD19 CAR T-cell therapy, was associated with efficacy and treatment-related neurological events among patients with relapsed/refractory mantle cell lymphoma treated within the ZUMA-2 trial.
Encorafenib/Binimetinib Combo Continues to Show Survival Benefits in BRAF V600-Mutant Melanoma
May 30th 2020, 11:23pm
The combination of encorafenib and binimetinib demonstrated continuing benefit in overall survival and progression-free survival for patients with BRAF V600–mutant melanoma.
CC-92480 Shows Encouraging Efficacy in First-in-Human Study for R/R Multiple Myeloma
May 30th 2020, 11:05pm
An ongoing study of CC-92480 in combination with dexamethasone demonstrated favorable activity and safety data in patients with heavily pretreated relapsed or refractory multiple myeloma.
Update Sustains OS Benefit With Encorafenib/Cetuximab Regimens in BRAF+ mCRC
May 30th 2020, 10:14pm
The latest results from the phase 3 BEACON CRC study continued to show an overall survival benefit for encorafenib plus cetuximab with or without binimetinib compared with cetuximab plus irinotecan-containing regimens in patients with BRAF V600E–mutated metastatic colorectal cancer.